human insulin


( Last Updated : October 6, 2021)
Generic Name:
human insulin
Project Status:
Complete
Therapeutic Area:
Diabetes mellitus
Manufacturer:
Eli Lilly Canada Inc.
Brand Name:
Entuzity KwikPen
Project Line:
Reimbursement Review
Project Number:
SR0672-000
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
‚ÄčTo improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open December 22, 2020
Call for patient/clinician input closed February 22, 2021
Clarification:

- Patient input submission received from Diabetes Canada

Submission received January 27, 2021
Submission accepted February 10, 2021
Review initiated February 11, 2021
Draft CADTH review report(s) provided to sponsor for comment April 30, 2021
Deadline for sponsors comments May 11, 2021
CADTH responses on draft review report(s) provided to sponsor June 04, 2021
Expert committee meeting (initial) June 16, 2021
Draft recommendation issued to sponsor June 29, 2021
Draft recommendation posted for stakeholder feedback July 08, 2021
End of feedback period July 22, 2021
Final recommendation issued to sponsor and drug plans August 05, 2021
Final recommendation posted August 23, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) August 19, 2021
CADTH review report(s) posted October 06, 2021